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Novelty and impact: Dose-dense chemotherapy is standard of care in high-risk early breast cancer; 
however, its role in HER2-positive patients is still uncertain. In this exploratory analysis of the 
GIM2 trial, we showed that the benefit of dose-dense chemotherapy appeared to be small (if any) in 
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escalation approaches in this setting. These findings may guide the choice of adjuvant 















Dose-dense adjuvant chemotherapy is standard of care in high-risk early breast cancer patients. 
However, its role in HER2-positive patients is still uncertain. In this exploratory analysis of the 
GIM2 trial, we investigated the efficacy of dose-dense chemotherapy in HER2-positive breast 
cancer patients with or without exposure to trastuzumab. In the GIM2 trial, node-positive early 
breast cancer patients were randomized to receive 4 cycles of 
(fluorouracil)epirubicin/cyclophosphamide followed by 4 cycles of paclitaxel administered every 2 
(dose-dense) or 3 (standard-interval) weeks. After approval of adjuvant trastuzumab, protocol was 
amended in April 2006 to allow use of trastuzumab for 1 year after chemotherapy completion in 
HER2-positive patients. The efficacy of dose-dense chemotherapy in terms of disease-free survival 
(DFS) and overall survival (OS) was assessed according to HER2 status and trastuzumab use. Out 
of 2,003 breast cancer patients, HER2 status was negative/unknown in 1,551 patients; among the 
452 patients with HER2-positive breast cancer, chemotherapy alone or followed by trastuzumab 
was given to 320 and 132 patients, respectively. Median follow-up was 8.1 years. No significant 
interaction between HER2 status, trastuzumab use and chemotherapy treatment was observed for 
both DFS (p=0.698) and OS (p=0.708). Nevertheless, there was no apparent benefit in the HER2-
positive group treated with trastuzumab (DFS: HR, 0.99; 95% CI 0.52-1.89; OS: HR, 0.95; 95% CI 
0.37-2.41). Although dose-dense chemotherapy was associated with a significant survival 
improvement in high-risk breast cancer patients, its benefit appeared to be smaller (if any) in 
















Polychemotherapy following surgical resection remains a mainstay adjuvant treatment for many 
patients with early breast cancer.1,2 Although the combination of docetaxel and cyclophosphamide 
can be considered a valid alternative in some cases,3 the sequential use of a taxane with 
anthracycline- and cyclophosphamide-based chemotherapy represents the preferred approach in 
high-risk patients.4 In breast cancer patients at higher risk of disease recurrence, dose-dense 
chemotherapy obtained by shortening the interval between treatment cycles is associated with a 
significant improvement in survival outcomes.5 
 
Before the introduction of adjuvant anti-HER2 targeted therapy, the efficacy of dose-dense 
chemotherapy was demonstrated also in patients with HER2-positive early breast cancer.5,6 
However, chemotherapy plus anti-HER2 targeted therapy is the current standard of care in this 
setting.7 Three studies showed the feasibility (in terms of no increased likelihood of developing 
cardiac events) of administering dose-dense anthracycline- and taxane-based chemotherapy in 
combination with adjuvant trastuzumab in patients with HER2-positive early breast cancer.8–10 
However, none of these studies was designed to investigate the superiority of the dose-dense 
schedule over standard-interval chemotherapy. Therefore, the need for prescribing dose-dense 
chemotherapy in patients with HER2-positive early breast cancer undergoing adjuvant anti-HER2 
targeted therapy remains unknown.11 
 
The Gruppo Italiano Mammella (GIM) 2 trial (ClinicalTrials.gov Identifier: NCT00433420) is one 
of the largest studies that investigated the efficacy of dose-dense chemotherapy as adjuvant 
treatment of high-risk early breast cancer patients.12 The trial was conducted at the turn of the years 
in which adjuvant trastuzumab became standard of care in HER2-positive breast cancer. Therefore, 
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undergo anti-HER2 targeted therapy. This represented a unique opportunity to explore the efficacy 
of dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after 
the introduction of adjuvant trastuzumab. 
 
MATERIALS AND METHODS 
Study design and participants 
Details of the GIM2 study design were previously reported.12,13 Briefly, GIM2 was a multicenter, 
open-label, randomized phase III study including patients aged 18-70 years who had undergone 
radical surgery for a histologically confirmed invasive breast cancer with metastasis in at least one 
axillary lymph node. 
 
According to the criteria in force at the time of study conduction, HER2 status was defined as 
positive in the presence of at least 10% of cells with HER2 expression assessed by 
immunohistochemistry or in the presence of gene amplification documented by in-situ hybridization 
assay. The presence of at least 10% of positive cells by immunohistochemical analysis was the 
criteria to define the tumor positive for estrogen and/or progesterone receptors. 
 
The trial was conducted at 81 Italian centers. The Institutional Review Boards of all participating 
centers approved the GIM2 protocol and all enrolled patients provided written informed consent 




In the GIM2 trial, eligible patients were randomized in a 1:1:1:1 ratio to one of the following 4 
arms: standard-interval fluorouracil, epirubicin and cyclophosphamide (FEC) followed (-) by 
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cycles (4 of anthracycline-based chemotherapy and 4 of single agent taxane) and the dose of 
chemotherapy agents (fluorouracil at 600 mg/m2, epirubicin at 90 mg/m2, cyclophosphamide at 600 
mg/m2 and paclitaxel at 175 mg/m2) were the same in all treatment arms. In the dose-dense arms, 
administration of subcutaneous pegfilgrastim (6 mg) was mandatory 24-72 hours after 
chemotherapy.14  
 
After approval of adjuvant trastuzumab by the Italian regulatory authorities, an amendment in April 
2006 allowed the administration of the anti-HER2 monoclonal antibody for 1 year after 
chemotherapy in patients with HER2-positive disease. Patients with hormone receptor-positive 
disease received adjuvant endocrine therapy following completion of chemotherapy according to 
local guidelines. 
 
Objectives and endpoints  
This exploratory analysis aimed at investigating a potential interaction between HER2 status, 
trastuzumab use and chemotherapy by evaluating the efficacy of dose-dense chemotherapy in the 
subgroup of patients with HER2-positive breast cancer with or without subsequent exposure to 
adjuvant trastuzumab and in those with HER2-negative/unknown disease. 
 
Outcomes were compared between three groups of patients: HER2-positive group not exposed to 
adjuvant trastuzumab (HER2-positive no trastuzumab group), HER2-positive group exposed to 
adjuvant trastuzumab (HER2-positive trastuzumab group) and HER2-negative/unknown group. 
 
As in the main GIM2 trial,12 disease-free survival (DFS) was the primary endpoint; overall survival 
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Sample size calculation and statistical assumptions of the GIM2 primary objective were previously 
described.12 The present analysis focusing on the efficacy of dose-dense chemotherapy according to 
HER2 status and trastuzumab use was not preplanned in the trial protocol, and the power of the 
statistical analyses was not prespecified. For the purpose of the present analysis, the two dose-dense 
arms were considered together as well as the two standard-interval arms. The 88 patients included 
in the 5 centers that refused randomization to the dose-dense arms were excluded from this analysis 
(Figure 1). 
 
DFS and OS were defined as previously described.12 The heterogeneity of treatment effect (dose-
dense vs. standard-interval) according to HER2 status and trastuzumab use was investigated by 
including in each final model (for DFS and OS) an interaction term representing the modification of 
the effect of dose-dense chemotherapy in patients with HER2-positive disease treated with or 
without trastuzumab. For descriptive purposes, DFS and OS in patients assigned to dose-dense or 
standard-interval chemotherapy were also compared separately within each of the three groups of 
interest (HER2-positive no trastuzumab, HER2-positive trastuzumab and HER2-
negative/unknown). 
 
DFS and OS probabilities were computed according to the Kaplan-Meier method and the log-log 
method was used to calculate confidence intervals (CI) of survival time probabilities. To estimate 
treatment effect, unadjusted and adjusted hazard ratios (HRs) with 95% CI were calculated with the 
Cox proportional hazards model. The variables included in the multivariate Cox regression models 
were age, type of surgery, tumor size, number of lymph nodes, tumor grade, Ki67, hormone 
receptor status and endocrine therapy. Likelihood ratio test was applied to test the contribution of 
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As previously described12, adverse events were assessed clinically as well as by hematological and 
biochemical measurements throughout chemotherapy and were graded according to the National 
Cancer Institute common toxicity criteria version 2.0.  
 
All reported statistical analyses were based on the intention-to-treat population. All statistical tests 
were 2-sided, and p values < 0.05 were considered statistically significant. STATA 13.1 (StataCorp. 
2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP) was used to 
perform all statistical analyses.  
 
Data availability 
Data can be made available upon reasonable request to the corresponding author.  
 
RESULTS 
Between April 24, 2003 and July 3, 2006, 2,003 breast cancer patients were randomized to receive 
dose-dense (n=1,002) or standard-interval (n=1,001) chemotherapy (Figure 1).  
Among these patients, HER2 status was negative in 1,243 (62.0%), unknown in 308 (15.4%) and 
positive in 452 (22.6%) cases. Out of 452 patients with HER2-positive breast cancer, 320 (70.8%) 
received chemotherapy alone without trastuzumab while 132 (29.2%) received trastuzumab at the 
completion of chemotherapy. Table 1 reports baseline patient and tumor characteristics in the three 
groups of interest.  
 
Almost 90% of the patients in all treatment groups completed the planned number of chemotherapy 
cycles (Supporting Information Table S1). Supporting Information Table S2 reports the rate and 
grade of the adverse events occurring in at least 5% of the patients in the dose-dense and standard-
interval arms of the three groups. In terms of grade 3-4 adverse events, neutropenia was more 
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53.3%) while those in the dose-dense arms tended to developed more often anemia (ranging 
between 1.2% and 1.7%), myalgia (ranging between 1.7% and 3.3%) and ALT elevation (ranging 
between 1.2% and 3.4%). The highest rate of grade 3-4 asthenia (10.2%) was observed in the dose-
dense arms of the HER2-positive trastuzumab group. There were no cases of treatment-related 
deaths. 
 
Median follow-up was 8.1 years (IQR, 7.0-9.3). Number and type of survival events in the three 
cohorts are reported in Table 2. No significant interaction between HER2 status, trastuzumab use 
and chemotherapy treatment was observed for both DFS (univariate p=0.698 and multivariate 
p=0.705) and OS (univariate p=0.708 and multivariate p=0.826). Nevertheless, the benefit of dose-
dense chemotherapy appeared to be smaller in the HER2-positive trastuzumab group.  
In the HER2-positive no trastuzumab group, DFS at 7 years was 72.1% and 64.4% in the dose-
dense and standard-interval arms, respectively (HR, 0.78; 95% CI 0.53-1.13; adjusted HR, 0.79; 
95% CI 0.53-1.17; Figure 2A). OS at 7 years was 85.2% and 78.6% in the dose-dense and standard-
interval arms, respectively (HR, 0.63; 95% CI 0.37-1.07; adjusted HR, 0.59; 95% CI 0.34-1.03; 
Figure 3A).  
In the HER2-positive trastuzumab group, DFS at 7 years was 68.7% and 72.3% in the dose-dense 
and standard-interval arms, respectively (HR, 0.99; 95% CI 0.52-1.89; adjusted HR, 0.71; 95% CI 
0.35-1.42; Figure 2B). OS at 7 years was 84.9% and 86.1% in the dose-dense and standard-interval 
arms, respectively (HR, 0.95; 95% CI 0.37-2.41; adjusted HR, 0.91; 95% CI, 0.31-2.68; Figure 3B).  
In the HER2-negative/unknown group, DFS at 7 years was 78.7% and 72.1% in the dose-dense and 
standard-interval arms, respectively (HR, 0.74; 95% CI 0.61-0.89; adjusted HR, 0.72; 95% CI 0.59-
0.87; Figure 2C). OS at 7 years was 90.9% and 85.3% in the dose-dense and standard-interval arms, 











This article is protected by copyright. All rights reserved.
11 
 
Comparing DFS of the HER2-positive groups with that of the HER2-negative/unknown group 
among patients that received standard-interval chemotherapy, univariate HRs were 1.27 (95% CI 
0.95-1.70) in the HER2-positive no trastuzumab group (adjusted HR, 0.96; 95% CI 0.71-1.30) and 
0.93 (95% CI 0.59-1.47) in the HER2-positive trastuzumab group (adjusted HR, 0.81; 95% CI 0.50-
1.31) (Figure 4A). For OS, univariate HRs were 1.32 (95% CI 0.90-1.94) in the HER2-positive no 
trastuzumab group (adjusted HR, 0.95; 95% CI 0.63-1.43) and 0.84 (95% CI 0.44-1.61) in the 
HER2-positive trastuzumab group (adjusted HR, 0.67; 95% CI 0.34-1.30) (Figure 4B).  
Comparing DFS of the HER2-positive groups with that of the HER2-negative/unknown group 
among patients that received dose-dense chemotherapy, univariate HRs were 1.35 (95% CI 0.99-
1.84) in the HER2-positive no trastuzumab group (adjusted HR, 1.20; 95% CI 0.87-1.66) and 1.25 
(95% CI 0.76-2.05) in the HER2-positive trastuzumab group (adjusted HR, 0.92; 95% CI 0.55-1.56) 
(Figure 4C). For OS, univariate HRs were 1.27 (95% CI 0.81-2.00) in the HER2-positive no 
trastuzumab group (adjusted HR, 1.09; 95% CI 0.68-1.74), and 1.28 (95% CI 0.62-2.63) in the 
HER2-positive trastuzumab group (adjusted HR, 0.93; 95% CI 0.43-2.00) (Figure 4D).  
 
Results of the Cox regression model for all the variables evaluated in the study are reported as 




To our knowledge, this is the first analysis exploring the efficacy of dose-dense adjuvant 
chemotherapy in patients with HER2-positive disease receiving adjuvant trastuzumab. At a median 
follow-up of 8.1 years, we showed that dose-dense chemotherapy significantly improved both DFS 
and OS of patients with HER2-negative/unknown breast cancer. Although no significant interaction 
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chemotherapy appeared to be smaller (if any) in the subgroup of patients with HER2-positive 
disease who received adjuvant trastuzumab. 
 
At a longer follow-up than previously reported in other dose-dense adjuvant chemotherapy trials, 
our analysis confirms the benefit of shortening the interval between treatment cycles in high-risk 
early breast cancer patients (with a 6.6% and 5.6% absolute improvement in DFS and OS at 7 years, 
respectively, in the HER2-negative/unknown population). This is in line with the findings from the 
recent Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis 5 supporting the 
use of dose-dense chemotherapy as the preferred adjuvant chemotherapy approach in patients 
deemed at higher risk of disease recurrence. In terms of adverse events, as also confirmed in our 
analysis, the rate of grade 3-4 neutropenia is lower with the use of dose-dense chemotherapy 
considering that primary prophylaxis with granulocyte colony-stimulating factor is mandatory in 
this setting.5 On the other hand, higher rate of grade 3-4 anemia is expected when shortening the 
interval between cycles but with no difference in cardiotoxicity or other non-hematological 
toxicities and neither in treatment compliance.5 Nevertheless, despite the positive risk-benefit ratio 
in the overall high-risk breast cancer population, in the era of treatment personalization and de-
escalation, it remains crucial to better define the population of patients that really benefit from this 
approach. 
 
Before the introduction of targeted therapies, a retrospective analysis conducted within the phase III 
MIG1 trial in patients with HER2-positive disease demonstrated that anthracycline-based dose-
dense chemotherapy is highly effective in this setting.6 Similarly, the EBCTCG meta-analysis, in 
which the majority of patients with HER2-positive disease were not exposed to targeted therapy, 
showed that dose-dense chemotherapy was effective irrespectively of HER2 status.5 Consistently 
with previous findings, our analysis showed apparent similar absolute and relative DFS and OS 
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schedule in patients with HER2-positive tumors not treated with adjuvant trastuzumab and those 
with HER2-negative/unknown disease. The high proliferative capability and their sensitivity to 
anthracycline-based chemotherapy 15 may explain the potential predictive value of HER2-positivity 
in the absence of targeted therapy for the efficacy of dose-dense regimens. Nevertheless, it should 
be highlighted that trastuzumab has radically changed the prognosis of patients with HER2-positive 
early breast cancer converting this tumor from an aggressive subtype to one with good outcomes; 
thus, anti-HER2 targeted therapy remains the cornerstone in the treatment of this disease.16 In our 
analysis, we also explored the benefit of introducing adjuvant trastuzumab in patients with HER2-
positive disease. Considering that patients receiving anti-HER2 targeted therapy had to survive long 
enough to be offered trastuzumab, a potential lead-time bias cannot be excluded in this analysis. 
However, despite this potential bias, our data do not exhibit a severe violation of the proportional 
hazards assumption to seriously affect our findings when the effect of the treatments within the 
HER2 / trastuzumab strata is compared (data not shown). As expected, we observed that patients 
with HER2-positive tumors treated with dose-dense or standard-interval chemotherapy without 
adjuvant trastuzumab have generally experienced worse DFS and OS than those exposed to 
adjuvant trastuzumab or patients with HER2-negative/unknown disease. Therefore, chemotherapy 
escalation approaches should be considered with particular cautious in this setting where anti-HER2 
blockade is the mainstay therapy.16,17 
 
In the current anti-HER2 targeted therapy era, the benefit of dose-dense chemotherapy remains 
unknown when trastuzumab is administered.11 Differently from previous studies in which all 
patients received dose-dense chemotherapy,8–10 we could specifically explore whether dose 
intensification may benefit patients treated with adjuvant trastuzumab. Despite no significant 
interaction was observed between HER2 status, trastuzumab treatment and the effect of dose-dense 
chemotherapy, no apparent absolute and relative differences in DFS and OS could be observed 
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patients who received trastuzumab. Similar conclusions were reached in a recently presented 
secondary analysis of the PANTHER trial showing no apparent significant benefit of dose-dense 
chemotherapy in patients with HER2-positive early breast cancer who underwent adjuvant 
trastuzumab.18 These data are of particular relevance in the current chemotherapy de-escalation era 
thanks to the availability of effective anti-HER2 targeted agents.19 Based on recent findings, 
patients with stage I HER2-positive breast cancer are candidates to receive adjuvant weekly 
paclitaxel and trastuzumab.17 On the contrary, patients with stage II-III disease may benefit from a 
neoadjuvant approach with taxane-based chemotherapy (with or without anthracyclines) plus dual 
anti-HER2 blockade with trastuzumab and pertuzumab,20,21 and the possibility to switch to 
trastuzumab-emtansine (T-DM1) in the case of residual disease at surgery.22 In such scenario of 
increased optimization of anti-HER2 blockade, we may speculate that increasing the dose intensity 
of chemotherapy in the early setting might not be considered a needed treatment strategy. 
 
Our findings should be considered with caution because of some important limitations. This is an 
exploratory analysis that was not preplanned in the original protocol. No strong conclusions can be 
derived considering both the wide 95% CI and that the observed differences within the cohort of 
patients with HER2-positive disease failed to achieve statistical significance. This may be due also 
to lack of power based on the small number of patients with HER2-positive disease particularly in 
the cohort treated with adjuvant trastuzumab. For this same reason, despite our original intent 
considering the different behavior of HER2-positive tumors according to hormone receptor status,23 
it was not possible to explore potential differences in treatment effect between patients with 
hormone receptor-positive or negative disease. In addition, HER2 testing was performed locally in 
an era in which there was no specific recommendation on the type of test to be used. Finally, in 
terms of safety, cardiotoxicity was not systematically collected in the trial. Despite these limitations, 
importantly, our analysis was conducted within a large multicenter randomized trial with a median 
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dose-dense chemotherapy in the anti-HER2 targeted therapy era. Notably, it will be difficult to 
replicate these findings within other dose-dense studies considering that in the older trials most of 
the patients with HER2-positive disease did not receive anti-HER2 therapy 5 while in the more 
recent ones all of them received trastuzumab.18,24 Therefore, this analysis retains a unique value 
with important clinical implications for the choice of the best adjuvant chemotherapy regimen.  
 
In conclusion, our exploratory analysis of the GIM2 trial showed that dose-dense chemotherapy 
remains associated with a significant survival improvement in high-risk early breast cancer patients 
with HER2-negative/unknown disease. Although no significant interaction between HER2 status, 
trastuzumab use and chemotherapy was observed, the benefit of dose-dense chemotherapy appeared 
to be smaller (if any) in patients with HER2-positive who received adjuvant trastuzumab. Results of 
the FeDeriCa trial (NCT03493854) are awaited to better assess the need of chemotherapy escalation 
approaches in this setting. 
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Figure 1. The Consolidated standards of reporting trials (CONSORT) flow diagram for the GIM2 
study. 
 
Abbreviations: FEC, fluorouracil, epirubicin, cyclophosphamide; EC, epirubicin, 
cyclophosphamide; P, paclitaxel; DFS, disease-free survival; OS, overall survival. 
 
Figure 2. Disease-free survival for the comparison between dose-dense and standard-interval 
chemotherapy: HER2-positive no trastuzumab group (A); HER2-positive trastuzumab group (B); 
HER2-negative/unknown group (C). 
 
Abbreviations: HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence intervals. 
 
Figure 3. Overall survival for the comparison between dose-dense and standard-interval 
chemotherapy: HER2-positive no trastuzumab group (A); HER2-positive trastuzumab group (B); 
HER2-negative/unknown group (C). 
 
Abbreviations: HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence intervals. 
 
Figure 4. Disease-free survival in the standard interval cohort A); Overall survival in the standard 
interval cohort B); Disease-free survival in the dose-dense cohort C); Overall survival in the dose-
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Abbreviations: HER2+ / No T, HER2-positive no trastuzumab group; HER2+ / T, HER2-positive 
trastuzumab group; HER2- / Unk, HER2-negative/unknown group; HR, hazard ratio; aHR, adjusted 
hazard ratio; CI, confidence intervalsl.  
 
Table 1. Baseline patient and tumor characteristics 
 
 HER2-positive 

































































































































ER and/or PR positive 













































































Tamoxifen (± GnRHa) 

























*The percentages were calculated on the total number of patients with hormone receptor-positive 
breast cancer 
Abbreviations: pT, pathologic tumor stage; pN, pathologic nodal stage; G, tumor grade; HR, 
hormone receptor; ER, estrogen receptor; PR, progesteron receptor; CT, chemotherapy; FEC, fl 
uorouracil, epirubicin, and cyclophosphamide; EC, epirubicin and cyclophosphamide; DD, dose 
dense; SI, standard interval; GnRHa, gonadotropin-releasing hormone agonist; AI, aromatase 
inhibitor. 
 






















No events 212 (66.3) 95 (72.0) 1,117 (72.0)  
0.116 
Loco-regional recurrence only 31 (9.7) 10 (7.6) 89 (5.7) 0.032 
Distant recurrence 61 (19.1) 25 (18.9) 245 (15.8) 0.251 
Second primary malignancy 7 (2.2) 0 (-) 41 (2.6) 0.136 
Second primary breast cancer 5 (1.6) 1 (0.8) 33 (2.1) 0.632 
Death without any disease-free 
survival event 
4 (1.3) 1 (0.8) 26 (1.7) 0.841 
Death with some disease-free 
survival event 
53 (16.6) 17 (12.9) 194 (12.5) 0.153 
 











This article is protected by copyright. All rights reserved.
2,091 patients randomly assigned 
 88 excluded from current analysis  
   (not randomized to dose-dense arms) 
320 HER2-positive/no trastuzumab  
   108 developed DFS events 
     57 developed OS events 
1,002 assigned to dose-dense chemotherapy 
(500 to FEC-P and 502 to EC-P) 
     166  HER2-positive no trastuzumab 
       60  HER2-positive trastuzumab 
     617  HER2-negative  
     159  HER2-unknown 
2,003 included in the current analysis 
1,001 assigned to standard interval chemotherapy 
(500 to FEC-P and 501 to EC-P) 
     154 HER2-positive no trastuzumab 
       72 HER2-positive trastuzumab 
     626  HER2-negative  
     149  HER2-unknown 
132 HER2-positive/trastuzumab  
   37 developed DFS events 
   18 developed OS events 
1,551 HER2-negative/unknown 
   434 developed DFS events 
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HER2-positive no trastuzumab 
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166 156 139 130 123 115 108 99 65 35 11Dose-dense
154 138 125 115 105 100 91 80 60 30 13Standard
Number at risk
0 1 2 3 4 5 6 7 8 9 10
Time Since Random Assignment (years)
Standard
Dose-dense
HER2+ / No trastuzumab cohort
A	
HR, 0.78; 95% CI 0.53-1.13 
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60 59 52 44 44 43 41 29 21 13 5Dose-dense
72 66 55 52 51 49 48 35 22 13 9Standard
Number at risk
0 1 2 3 4 5 6 7 8 9 10
Time Since Random Assignment (years)
Standard
Dose-dense
HER2+ / Trastuzumab cohort
HER2-positive trastuzumab B	
HR, 0.99; 95% CI 0.52-1.89 
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776 742 692 659 622 590 558 488 344 189 82Dose-dense
775 725 662 606 578 548 520 430 300 170 80Standard
Number at risk
0 1 2 3 4 5 6 7 8 9 10
Time Since Random Assignment (years)
Standard
Dose-dense
HER2- / Unk cohort
C	
HR, 0.74; 95% CI 0.61-0.89 
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HER2-positive no trastuzumab A	
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166 162 158 152 148 143 129 116 82 43 13Dose-dense
154 147 140 131 122 120 110 98 76 40 17Standard
Number at risk
0 1 2 3 4 5 6 7 8 9 10
Time Since Random Assignment (years)
Standard
Dose-dense
HER2+ / No trastuzumab cohort
HR, 0.63; 95% CI 0.37-1.07 










This article is protected by copyright. All rights reserved.
HER2-positive trastuzumab B	
10 




















60 60 56 52 50 49 46 33 21 13 5Dose-dense
72 72 68 62 61 55 54 43 26 15 10Standard
Number at risk
0 1 2 3 4 5 6 7 8 9 10
Time Since Random Assignment (years)
Standard
Dose-dense
HER2+ / Trastuzumab cohort
HR, 0.95; 95% CI 0.37-2.41 
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776 754 727 706 682 662 634 553 389 225 100Dose-dense
775 745 718 678 649 623 590 500 345 200 101Standard
Number at risk
0 1 2 3 4 5 6 7 8 9 10
Time Since Random Assignment (years)
Standard
Dose-dense
HER2- / Unk cohort
HR, 0.66; 95% CI 0.50-0.86 
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775 725 662 606 578 548 520 430 300 170 80HER2- / Unk
72 66 55 52 51 49 48 35 22 13 9HER2+ / T
154 138 125 115 105 100 91 80 60 30 13HER2+ / No T
Number at risk
0 1 2 3 4 5 6 7 8 9 10
Time Since Random Assignment (years)




HER2- / Unk: 
HER2+ / No T: 
HER2+ / T: 
Reference group 
HR, 1.27; 95% CI 0.95-1.70 / aHR, 0.96; 95% CI 0.71-1.30  
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775 745 718 678 649 623 590 500 345 200 101HER2- / Unk
72 72 68 62 61 55 54 43 26 15 10HER2+ / T
154 147 140 131 122 120 110 98 76 40 17HER2+ / No T
Number at risk
0 1 2 3 4 5 6 7 8 9 10
Time Since Random Assignment (years)




HER2- / Unk: 
HER2+ / No T: 
HER2+ / T: 
Reference group 
HR, 1.32; 95% CI 0.90-1.94 / aHR, 0.95; 95% CI 0.63-1.43  
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776 742 692 659 622 590 558 488 344 189 82HER2- / Unk
60 59 52 44 44 43 41 29 21 13 5HER2+ / T
166 156 139 130 123 115 108 99 65 35 11HER2+ / No T
Number at risk
0 1 2 3 4 5 6 7 8 9 10
Time Since Random Assignment (years)




HER2- / Unk: 
HER2+ / No T: 
HER2+ / T: 
Reference group 
HR, 1.35; 95% CI 0.99-1.84 / aHR, 1.20; 95% CI 0.87-1.66  
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776 754 727 706 682 662 634 553 389 225 100HER2- / Unk
60 60 56 52 50 49 46 33 21 13 5HER2+ / T
166 162 158 152 148 143 129 116 82 43 13HER2+ / No T
Number at risk
0 1 2 3 4 5 6 7 8 9 10
Time Since Random Assignment (years)




HER2- / Unk: 
HER2+ / No T: 
HER2+ / T: 
Reference group 
HR, 1.27; 95% CI 0.81-2.00 / aHR, 1.09; 95% CI 0.68-1.74  
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